A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
收藏DataCite Commons2025-10-10 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011852/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate efficacy and safety of brigatinib in Japanese participants with anaplastic lymphoma kinase (ALK)-positive NSCLC.
提供机构：
Vivli
创建时间：
2025-10-09
